Published online Apr 26, 2017. doi: 10.13105/wjma.v5.i2.63
Peer-review started: October 8, 2016
First decision: November 29, 2016
Revised: February 17, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: April 26, 2017
Processing time: 204 Days and 16.4 Hours
To assess mucin expression in pancreatic premalignant and malignant states, and to establish its role as a prognostic marker.
English Medical literature searches were conducted for “mucin” and “pancreas”. Observational studies were included. Meta-analysis was performed by using Comprehensive meta-analysis software. Pooled odds ratios and 95%CIs were calculated.
Out of 949 eligible papers we found 20 according to the inclusion criteria, including 4262 patients, published till May 31, 2016. Mucin expression increased in pancreatic lesions with OR 10.206 (95%CI: 4.781-21.781, P < 0.0001). Measure of heterogeneity was high: Q = 296.973, df (Q) = 55.00, I2 = 81.48%. We found a significant increase in the expression of MUC2, MUC4 and MUC5AC, 13.39, 118.43 and 13.91 times respectively, in pancreatic lesion in comparison with normal pancreatic tissue, and decreased expression of MUC5B.
Mucin expression may serve as prognostic marker for transformation of intraductal papillary mucinous neoplasms to ductal adenocarcinoma, for aggressiveness of the pancreatic tumor, and as targets for potential therapy.
Core tip: There is a higher mucin expression in intraductal papillary mucinous neoplasms (IPMN) and ductal pancreatic cancer. Mucin expression may be a bad prognostic factor. MUC2, MUC4, MUC5AC and probably MUC1, are expressed in IPMN advanced to ductal adenocarcinoma. These mucins are also bad prognostic factors for ductal adenocarcinoma.